US7727984 — Medicaments for the treatment of chronic obstructive pulmonary disease
Composition of Matter · Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2027-01-19 · 1y remaining
What this patent protects
This patent protects a pharmaceutical composition containing the compound olodaterol hydrochloride, used to treat chronic obstructive pulmonary disease.
USPTO Abstract
A pharmaceutical composition comprising a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, C1-C4-alkyl, halogen, OH, or âOâC1-C4-alkyl; R2 is hydrogen, C1-C4-alkyl, halogen, OH, or âOâC1-C4-alkyl; R3 is hydrogen, C1-C4-alkyl, OH, halogen, âOâC1-C4-alkyl, âOâC1-C4-alkylene-COOH, or âOâC1-C4-alkylene-COâOâC1-C4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.